Type 2 Diabetes Mellitus KOL Insight : Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase IIIb/IV EXSCEL study evaluating the effect of once-weekly Bydureon versus placebo in type-2 diabetics; the FDA’s boxed warning on risks of foot amputations for Johnson & Johnson’s canagliflozin (Invokana/Invokamet) based on data from the CANVAS and CANVAS-R trials; and EnteroMedics reporting of three-year data from its VBloc DM2 study in obese type 2 diabetics.

Business questions

• How do KOLs view the data for AstraZeneca’s EXSCEL study for Bydureon?
• Bydureon did not show superiority for cardiovascular end-point; will it have a role in type 2 diabetes treatment algorithm? If so where?
• How do KOLs see Bydureon in relation to Trulicity and other GLP-1s?
• How do KOLs see the FDA’s boxed warning for canagliflozin?
• How do KOLs rate Invokana and other SGLT-2 inhibitors?
• What potential do KOLs think EnteroMedics vBloc implant device and what challenges do they foresee?
• Will vBloc find a role in the treatment of diabetic patients?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.